Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi EXTON, PA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of...

[Latest] Global Aesthetics Injectables Market Size/Share Worth USD 35,976.2 Million by 2033 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) Austin, TX, USA, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Aesthetics Injectables Market Size, Trends and Insights By Product Type...

EPIZYME ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of EPZM and Encourages Investors to Contact the Firm NEW YORK, July 01, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...

GENFIT : Ipsen et GENFIT concluent un accord de licence exclusif pour elafibranor, un composé évalué en Phase III dans la cholangite biliaire primitive, dans le cadre d’un partenariat global de long terme GENFIT : Ipsen et GENFIT concluent un accord de licence exclusif pour elafibranor, un composé évalué en Phase III dans la cholangite biliaire primitive, dans le cadre d’un partenariat global de long...

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership ...